Dapiglutide is under clinical development by Zealand Pharma and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dapiglutide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dapiglutide overview

Dapiglutide (ZP-7570) is under development for the treatment of obesity and other metabolic and gastrointestinal diseases. It acts by targeting glucagon like peptide receptor 1 and 2. It is administered through subcutaneous route.

It was also under development for the treatment of short bowel syndrome.

Zealand Pharma overview

Zealand Pharma (Zealand) is a biotechnology company. It discovers, designs and develops peptide-based medicines that target specialty diseases. The company’s product portfolio comprises glepaglutide which is a long-acting GLP-2 analog in development for the treatment of short bowel syndrome and dasiglucagon is used against type 1 diabetes and congenital hyperinsulinism. It also offers GLP1-GLU which is used against several cardio-metabolic diseases such as heart disease, ischemic stroke and liver diseases. Zealand conducts research and development and in-licensing programs. It has operations in Denmark and the US. ealand is headquartered in Soeborg, Denmark.

For a complete picture of Dapiglutide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.